COVID-19: Gilead To Fill Remdesivir Supply Gap In EU
Coronavirus Reignites Compulsory Licensing Debate
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
You may also be interested in...
A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
The Therapeutic Goods Administration’s provisional approval for Gilead Sciences’ drug comes with a number of post-marketing obligations for the company.